Blood cancer journal 2023 Oct 11
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Related Questions
NGS results are pending
New answer by Medical Oncologist at The Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute (January 25, 2024)
It would be important to know what type of "favorable risk" AML the patients had and also what the current NGS shows. I would wait on NGS results to return to see what the opt...